Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TAI vs TACE for HCC with PVTT after Hepatectomy
NCT03192644Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2017
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Recurrence-Free Survival up to 60 months. Status: unknown.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03192644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192644.